A61K 39 - Medicinal preparations containing antigens or antibodies

Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
11/2011
11/08/2011	US8052977 DNA vaccine for Koi herpes virus (KHV) disease
11/08/2011	US8052975 Compounds and methods for treatment and diagnosis of chlamydial infection
11/08/2011	US8052974 Host cell specific binding molecules capable of neutralizing viruses and uses thereof
11/08/2011	US8052972 Remedies for inflammatory bowel diseases
11/08/2011	US8052971 Oral use of specific antibodies for intestinal health
11/08/2011	CA2653201C Compositions and uses of e3-gp19k for treating diabetes
11/08/2011	CA2555688C Methods of treating osteoarthritis with anti-il-6 or anti-il6 receptor antibodies
11/08/2011	CA2545086C Vaccine composition admixed with an alkylphosphatidylcholine
11/08/2011	CA2443290C Neurovirulent strain of the west nile virus and applications thereof
11/08/2011	CA2442182C Modulation of pd-1 interactions with its ligands
11/08/2011	CA2436180C Immunoregulatory antibodies and uses thereof
11/08/2011	CA2415399C Use of strains of the parapox ovis virus against organ fibrosis
11/08/2011	CA2362204C Immunogenic complexes and methods relating thereto
11/08/2011	CA2246352C Methods for inhibiting an immune response by blocking the gp39/cd40 and ctla4/cd28/b7 pathways and compositions for use therewith
11/08/2011	CA2226312C Method for purifying viruses by chromatography
11/08/2011	CA2153692C Recombinant anti-vla4 antibody molecules
11/03/2011	WO2011137441A2 Sparc binding aptamers and uses thereof
11/03/2011	WO2011137422A2 Methods and articles for preventing or reducing risk of developing a hyperallergenic immune system
11/03/2011	WO2011137354A2 Delivery proteins
11/03/2011	WO2011137344A2 Anti-s1p antibody treatment of patients with ocular disease
11/03/2011	WO2011137322A2 Methods and compositions for treating celiac disease
11/03/2011	WO2011137245A2 Lytic-peptide-her2/neu (human epidermal growth factor receptor 2) ligand conjugates and methods of use
11/03/2011	WO2011137114A1 Sparc binding antibodies and uses thereof
11/03/2011	WO2011136738A1 Universal vaccine against h5n1 lineages
11/03/2011	WO2011136378A1 Grafting material for genetic and cell therapy
11/03/2011	WO2011135869A1 Novel muc1 antibody
11/03/2011	WO2011135544A2 Methods and compositions for treating hepatitis with anti-cd3 immune molecule therapy
11/03/2011	WO2011135393A1 Autologous biological cancer vaccine
11/03/2011	WO2011135309A1 Vaccination method using microneedle arrays
11/03/2011	WO2011135304A1 Ncam-vase and neuroregeneration
11/03/2011	WO2011135075A1 Parapoxvirus expressing the vp60 major capsid protein of the rabbit haemorrhagic disease virus
11/03/2011	WO2011134899A1 Combination therapy of an afucosylated cd20 antibody with a mtor inhibitor
11/03/2011	WO2011134420A1 Detection and modulation of slit and roundabount (robo) mediated lymph vessel formation and uses thereof
11/03/2011	WO2011134163A1 Preparation method for inactivated vaccine of h9n2 subtype avian influenza and the product thereof
11/03/2011	WO2011134056A1 Methods and uses of tie2 binding and/or activating agents
11/03/2011	WO2011134026A1 Cosmetic methods and compositions
11/03/2011	WO2011133997A1 Cross-protective influenza vaccines
11/03/2011	WO2011110655A3 Immunogenic composition or vaccine against gram - negative bacterial, for example neiserial, infection or disease
11/03/2011	WO2011108008A3 Antibody for targeted induction of apoptosis, cdc and adcc mediated killing of cancer cells, tbl-cln1
11/03/2011	WO2011075606A3 Hyperglycosylated polypeptide variants and methods of use
11/03/2011	WO2011068953A3 Atoxic recombinant holotoxins of clostridium difficile as immunogens
11/03/2011	WO2011068934A3 Vaccine against neoplastic or cancerous lesions caused by human papillomavirus (hpv), procedures, uses and methods
11/03/2011	WO2011066378A3 Antagonists of il-6 to prevent or treat thrombosis
11/03/2011	WO2011050344A3 Cancer immunotherapy and method of treatment
11/03/2011	WO2011049346A3 Compositions for improving migration potential of stem cells
11/03/2011	WO2011046623A3 Hiv-1 antibodies
11/03/2011	WO2011044082A3 Compositions and methods for inhibiting madcam
11/03/2011	WO2011027990A3 Extracellular vesicles derived from gram-positive bacteria, and use thereof
11/03/2011	WO2011008863A8 Stereoisomer peptides and their polymer conjugates for hiv disease
11/03/2011	WO2010093993A3 Use of b lymphocyte stimulator protein antagonists to promote transplantation tolerance
11/03/2011	US20110271358 Human anti-pd-1, pd-l1, and pd-l2 antibodies and uses therefor
11/03/2011	US20110271357 Colon disease targets and uses thereof
11/03/2011	US20110271356 Hcv entry factor, occludin
11/03/2011	US20110269950 PHARMACEUTICAL COMPOSITION CONTAINING A STABILISED mRNA OPTIMISED FOR TRANSLATION IN ITS CODING REGIONS
11/03/2011	US20110269703 Method for treating or preventing thrombosis using dabigatran etexilate or a salt thereof with improved safety profile over conventional warfarin therapy
11/03/2011	US20110269674 Synthetic or natural peptides binding protein phosphatase 2a, identification method and uses
11/03/2011	US20110269122 Hereditary hemochromatosis gene
11/03/2011	US20110268805 Adjuvant incorporation in immunonanotherapeutics
11/03/2011	US20110268804 Targeting of antigen presenting cells with immunonanotherapeutics
11/03/2011	US20110268791 Porous nanoparticle supported lipid bilayer nanostructures
11/03/2011	US20110268789 Use of pituitary adenylate cyclase-activating polypeptide (pacap) and pacap analogs as adjunctive treatments with anticancer agents
11/03/2011	US20110268788 Immunotherapeutic agent suitable for the primary prophylaxis of tuberculosis
11/03/2011	US20110268767 Use of allogeneic cell lines to load antigen-presenting cells to elicit or eliminate immune responses
11/03/2011	US20110268765 Injectable Botulinum Toxin Formulations
11/03/2011	US20110268764 Immune response inducing preparations
11/03/2011	US20110268762 Immunization of avians by mucosal administration of non-replicating vectored vaccines
11/03/2011	US20110268761 Effective Sensitizing Dose of a Gelled Immunomodulating Topical Composition
11/03/2011	US20110268760 Salmonella vectored vaccines against chlamydia and methods of use
11/03/2011	US20110268758 Tuberculosis antigen detection assays and vaccines
11/03/2011	US20110268757 Use of phenol-soluble modulins for vaccine development
11/03/2011	US20110268756 Modified amyloid beta peptide
11/03/2011	US20110268754 Immunotherapy with in vitro-selected antigen-specific lymphocytes after nonmyeloablative lymphodepleting chemotherapy
11/03/2011	US20110268753 Process for regulating immune response
11/03/2011	US20110268751 Weekly Dosing Regimens for Anti-CD30 VC-PAB-MMAE Antibody Drug-Conjugates
11/03/2011	US20110268750 Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositions
11/03/2011	US20110268749 Treatment of cancer via targeting of il-13 receptor-alpha2
11/03/2011	US20110268748 NURR-1 Interacting Protein (NuIP)
11/03/2011	US20110268747 Stxbp1 as psychiatric biomarker in murine model system and their uses
11/03/2011	US20110268746 Human cytomegalovirus neutralizing antibodies and use thereof
11/03/2011	US20110268745 Antibodies Against Tissue Factor Pathway Inhibitor (TFPI)
11/03/2011	US20110268744 Method of Diagnosis of Infection by Mycobacteria and Reagents Therefor
11/03/2011	US20110268743 PROBIOTICS, SECRETORY IgA AND INFLAMMATION
11/03/2011	US20110268742 Pctp modulators in the treatment of acne, of seborrhoeic dermatitis or of hyperseborrhoea
11/03/2011	US20110268741 Immunotherapy for Contact Dermatitis Using Co-Signal Regulation
11/03/2011	US20110268740 Fully human influenza m2 specific antibodies
11/03/2011	US20110268739 Human binding molecules having killing activity against enterococci and uses thereof
11/03/2011	US20110268738 Antibodies Against Hmgb1 and Fragments Thereof
11/03/2011	US20110268737 Hla-g proteins and pharmaceutical uses thereof
11/03/2011	US20110268736 Method for treating congenital myopathy
11/03/2011	US20110268735 Multimeric constructs
11/03/2011	US20110268734 Preventive or therapeutic agent for psoriatic arthritis comprising il-6 antagonist as active ingredient
11/03/2011	US20110268733 ANTI-Siglec-15 ANTIBODY
11/03/2011	US20110268732 Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
11/03/2011	US20110268731 Methods of treating autoimmune disorders and/or inflammatory disorders
11/03/2011	US20110268730 Method for inhibiting bone resorption
11/03/2011	US20110268729 Treatment of amyotrophic lateral sclerosis by nogo-a-antagonist
11/03/2011	US20110268728 Solubility optimization of immunobinders
11/03/2011	US20110268727 Anti-interferon-alpha antibodies
11/03/2011	US20110268726 Anti-CD38 human antibodies and uses thereof
11/03/2011	US20110268725 Anti-NGF antibodies for the treatment of various disorders

1 ... 343 344 345 346 347 348 349 350 351 352 353 354 355 356 357 358 359 360 361 362 363 ... 1823